SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

VIVO BIO TECH

BSE: 511509 28 Jun 2025
Healthcare
₹ 36.88
Vivo Bio tech Ltd. specializes in Biotechnology within the Healthcare sector.

VIVO BIO TECH - Share Price & Details

Market Cap
₹67.9
High /Low
56.9 / 31.2
Stock P/E
9.33
Book Value
₹45.4
Dividend Yield
0.0
ROCE
12.6
ROE
₹11.0
Face Value
10.0
PEG Ratio
0.9
EVEBITDA
₹4.77
Debt
54.0
CMP / FCF
14.2
Debt to equity
₹0.69
NP Ann
7.28
High price all time
115.0
Piotroski score
₹6.0
Graham Number
65.8
No. Eq. Shares
1.84
Net CF
₹-0.11
Net profit
7.28
Price to book value
0.81
Interest Coverage
₹2.17
Low price all time
9.25
Industry PE
27.7
Reserves
₹60.7
Free Cash Flow
₹-4.01

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
VIVO BIO TECH LTD.NANANANA67.99.33
VASUNDHARA RASAYANS LTDNANANANA65.515.4
Jeevan Scientific Technology LNANANANA61.11,221

Peer Comparison Chart


About VIVO BIO TECH

Vivo Bio tech Ltd., with Security Code 511509, is a leading player in the Biotechnology industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

SINOVAC Board of Directors Alerts Shareholders to Advantech/Prime Success’ New Lawsuit, Which Threatens to Prevent Payment of US$55.00 Special Dividend to All Valid Shareholders

(16 Jun 2025)
The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products...
Read more →

Vivo Capital Issues Letter to Sinovac Biotech Shareholders Addressing the Company’s False and Misleading Claims

(12 Jun 2025)
Vivo Capital (“Vivo” or “we”), a leading global investment firm focused exclusively on healthcare and life sciences and an approximately 8%...
Read more →

Vivo Capital Issues Letter To Sinovac Biotech Shareholders

(12 Jun 2025)
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and...
Read more →

Vivo Capital Issues Letter to Sinovac Biotech Shareholders Addre

(12 Jun 2025)
Vivo Capital calls for fair dividend distribution and transparent governance at Sinovac Biotech (SVA). Grant Thornton resigns as Sinovac's...
Read more →

Vivo Capital issues letter to Sinovac Biotech shareholders

(12 Jun 2025)
Vivo Capital, an approximately 8% shareholder in Sinovac Biotech (SVA), sent a letter to shareholders. The letter said, “We, Vivo Capital,...
Read more →

Vivo Bio Tech Faces Financial Adjustments Amid Mixed Performance Indicators

(25 May 2025)
Vivo Bio Tech has recently experienced a score adjustment reflecting changes in its financial metrics. While the company reported a profit after tax of Rs...
Read more →